Comprehensive bioanalysis is vital at every stage of product development and is intertwined with the discovery of clinical capabilities. However, bioanalysis plays a critical role in drug development, consistently delivering accurate and reliable data, being subjected to rigorous scientific and regulatory review to ensure the success of preclinical and clinical programs. Besides, bioanalytical tools and services include capabilities akin to proprietary method development, validation, method transfer, and high throughput sample analysis and pharmacokinetic and toxicokinetic support, combined with automated data capture and reporting system.
Today, bioanalytical tools and services companies routinely develop, optimize, validate and apply quantitative bioanalytical methods to measure drug and metabolite concentrations for samples in almost biological fluid including both standard plasma, serum, cerebrospinal fluid (CSF), urine, and tissue and unconventional matrices like ocular, muscle, and bile. Like the companies optimize existing methods to increase efficiency and robustness that identify liabilities, and de-risk regulated issues. Development of bioanalytical methods essential for any drug development programme is one area where delays often occur, but with proper planning, it could be avoided. It is often necessary to move bioanalytical methods from one laboratory to another over the course of a drug development programme. Given today’s time pressures and the high cost of discovery and development in biopharmaceutical research, it is more important than ever that services, such as bioanalysis, are optimized for speed and success. To help business decision-makers streamline workflow, increase efficiency and remove bottlenecks Pharma Tech Outlook presents “Top 10 Bioanalytical Services Providers in Europe 2020,” for selecting the right partner for their respective ventures.